Tenvir-EM

Tenofovir Disoproxil Fumarate & Emtricitabine 300mg/200mg

Packs of 30 tablets

Tenvir-EM is indicated in combination with other antiretroviral agents for the treatment of HIV-1 infection in adults.

Composition

Each film coated tablet contains

• 300mg of Tenofovir Disoproxil Fumarate
• 200mg of Emtricitabine

Tenofovir Disoproxil Fumarate

It is an acyclic nucleoside phosphonate diester analog of adenosine monophosphate. It requires initial diester hydrolysis for conversion to tenofovir and subsequent phosphorylations by cellular enzymes to form tenofovir diphosphate. It inhibits the activity of HIV-1 reverse transcriptase by competing with the natural substrate deoxyadenosine 5`-triphosphate and, after incorporation into DNA, by DNA chain termination. It is a weak inhibitor of mammalian DNA polymerases alpha and beta, and mitochondrial DNA polymerase gamma.

Emtricitabine

It is a synthetic nucleoside analog of cytosine, is phosphorylated by cellular enzymes to form emtricitabine 5`-triphosphate. Emtricitabine 5`-triphosphate inhibits the activity of the HIV-1 reverse transcriptase by competing with the natural substrate deoxycytidine 5`-triphosphate and by being incorporated into nascent viral DNA which results in chain termination. Emtricitabine 5`- triphosphate is a weak inhibitor of mammalian DNA polymerase alpha, beta and epsilon and mitochondrial DNA polymerase gamma.

Contraindications

It is contraindicated in patients with previously demostrated hypersensitivity to any of the components of the products.

Dosage

The dose is one tablet (200mg of emtricitabine and 300mg of tenofovir disoproxil fumarate) once daily taken orally with or without food.

Delivery Time: 7-14 Days